Latigo Biotherapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Share count: As of November 2, 2026, the company had 66,299,347 shares of common stock outstanding.
- Filer status: The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
- Product pipeline: The filing references three named product candidates: onzotrigine, LTG-321, and LTG-418.
- Exchange listing: Common stock is listed on The Nasdaq Global Select Market under the ticker LTGO.
- Filing history note: The company indicated it has not been subject to regulatory filing requirements for the past 90 days, checking "No" on that cover-page item.
- Incorporation: The company is incorporated in Delaware, with principal offices in Thousand Oaks, California.
Latigo Biotherapeutics Q3 2026: Pipeline Focus and Filing Details
Latigo Biotherapeutics, Inc. (NASDAQ:LTGO), a Delaware-incorporated biotherapeutics company headquartered at 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, California 91320, submitted its quarterly report for the period ended September 30, 2026. According to the filing, the company had 66,299,347 shares of common stock outstanding as of November 2, 2026, with a par value of $0.0001 per share.
The filing identifies three product candidates central to the company's development activities: onzotrigine, LTG-321, and LTG-418. The registrant disclosed that forward-looking statements contained in the report relate to, among other things, the initiation, timing, and results of research and development programs and preclinical studies and clinical trials, as well as the timing and costs involved in obtaining regulatory approvals for each of the named candidates. The company noted that these statements "involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements."
The company confirmed it is an emerging growth company under the JOBS Act and has not elected to use the extended transition period for complying with new or revised financial accounting standards. The cover page further indicates that the company has not been subject to regulatory filing requirements for the full preceding 12-month period, as it checked "No" on that standard indicator. The registrant confirmed it is not a shell company.
What Was Disclosed
Latigo Biotherapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 66,299,347 shares outstanding as of November 2, 2026, its emerging growth company status, and pipeline candidates onzotrigine, LTG-321, and LTG-418.



Please wait processing your request...